Skip to content

Omini vs QuantuMDx

Omini logo

Omini

Multiplex blood testing platform to monitor chronic diseases like heart failure Project co-funded by the European Union

58 employees · est. 2019 · Suresnes, France

VS
QuantuMDx logo

QuantuMDx

Transforming Point of Need Multiplex Diagnostics

59 employees · est. 2008 · Newcastle Upon Tyne, United...

QuantuMDx is the older company (2019 vs 2008).

Side-by-Side Comparison

Omini QuantuMDx
Founded
2019 2008 older
Headquarters
Suresnes, France Newcastle Upon Tyne, United Kingdom
Employees
58 59
Industry
Biotechnology, Health Care Biotechnology, Health Care, Pharmaceutical
Funding Stage
Not tracked yet Venture round
Total Funding
$4.39M $59.77M
Funding Rounds
7 12
Services
Decentralized multiplex blood testing platform, Real-time biomarker monitoring, Portable diagnostic solutions, Affordable point-of-care tests Rapid Multiplex PCR Testing, Point-of-Care Diagnostic Devices, Development of Diagnostic Assays, Healthcare and Laboratory Solutions
Target Customers
Clinics, Community Healthcare Centers, Pharmacies, Home Healthcare Providers, Hospital-at-Home Programs, Healthcare Professionals Healthcare Professionals, Clinical Setting Managers, Laboratory Professionals, Testing Providers
Taxonomy
Biomarker MonitoringPoint-of-care Blood TestingChronic Disease ManagementMultiplex Blood TestingPortable Medical DevicesPersonalized Healthcare +3 MedTechMolecular DiagnosticsPoint Of Need DiagnosticsHand-held Diagnostic DevicesLow Cost DiagnosticsGenomic Sequencing +9
Website
ominilabs.com quantumdx.com
Omini logo

About Omini

Omini, founded in 2019 and headquartered in France, is revolutionizing chronic disease management through its groundbreaking technology. The biotechnology company is developing the first point-of-care blood biomarker monitoring platform, a step-change in healthcare solutions aimed at chronic disease...

QuantuMDx logo

About QuantuMDx

QuantuMDx, founded in 2008, is a forward-thinking MedTech company headquartered in the United Kingdom. With a commitment to innovation in the fields of Biotechnology, Health Care, and Pharmaceutical, the company is dedicated to advancing multiplex molecular diagnostic solutions under its slogan, "Tr...

Also comparing in this category

Comparing more than these two?

Get Omini, QuantuMDx and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Omini compare?

A PDF of Omini and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Omini was founded in 2019, based in Suresnes, France, with 58 employees. Omini, founded in 2019 and headquartered in France, is revolutionizing chronic disease management through its groundbreaking technology. The biotechnology company is developing the first point-of-care. QuantuMDx was founded in 2008, based in Newcastle Upon Tyne, United Kingdom, with 59 employees. QuantuMDx, founded in 2008, is a forward-thinking MedTech company headquartered in the United Kingdom. With a commitment to innovation in the fields of Biotechnology, Health Care, and Pharmaceutical,.
Omini has raised $4.39M and QuantuMDx $59.77M. Latest stage: QuantuMDx Venture round.
Both work in Biotechnology and Health Care.

Compare Omini with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Omini on 11 Jun 2025, and QuantuMDx on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout